Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-18 / J Immunol Res 2018;2018:3982942Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-06 / J Immunother Cancer 2018 Mar;6(1):19A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-298Dendritic cell therapy in melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-10-01 / Ann Transl Med 2017 Oct;5(19):386Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-04-20 / JCI Insight 2017 Apr;2(8)Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-10-18 / Oncoimmunology 2016;5(11):e1232237
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de